Isolation of mitochondrial mutation-specific T-cell receptors

It has been hypothesized that neoantigen-specific T cells play a major role in effective cancer immunotherapy, including neoantigen vaccines, immune checkpoint blockade (ICB) therapy, and adoptive T cell therapy using tumor-infiltrating lymphocytes (TILs). The major source of neoantigens are mutated proteins derived from non-synonymous mutations found in tumor genomic DNA. It’s highly conceivable that non-synonymous mutations found in tumor mitochondrial DNA (mtDNA) can also generate neoantigens that can be recognized by T-cell receptors (TCRs). This project contains two types of single-cell data. One is single-cell CITEseq (5' mRNA plus antibody feature barcode plus TCR) seqeuncing to identify antigen-specific TCRs. The other is single-cell ATAC-seq to detect chromatin accessiblities and mtDNA.